Barclays PLC Supernus Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 108,788 shares of SUPN stock, worth $3.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

108,788

Previous 108,788 -0.0%

Holding current value

$3.93 Million

Previous $3.39 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$25.77 - $35.16 $1.31 Million - $1.79 Million	51,005 Added 88.27%	108,788 $3.39 Million
Q2 2024 Aug 14, 2024	SELL	$25.99 - $33.85 $592,390 - $771,543	-22,793 Reduced 28.29%	57,783 $1.55 Million
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $602,465 - $781,582	-22,223 Reduced 21.62%	80,576 $2.75 Million
Q4 2023 Feb 15, 2024	BUY	$22.72 - $29.68 $1.09 Million - $1.42 Million	47,955 Added 87.44%	102,799 $2.98 Million
Q3 2023 Nov 07, 2023	BUY	$27.57 - $32.91 $28,148 - $33,601	1,021 Added 1.9%	54,844 $1.51 Million
Q2 2023 Aug 03, 2023	BUY	$29.91 - $38.73 $256,777 - $332,497	8,585 Added 18.98%	53,823 $1.62 Million
Q1 2023 May 04, 2023	BUY	$34.93 - $42.03 $22,215 - $26,731	636 Added 1.43%	45,238 $1.64 Million
Q4 2022 Feb 13, 2023	SELL	$31.09 - $37.88 $197,017 - $240,045	-6,337 Reduced 12.44%	44,602 $1.59 Million
Q3 2022 Nov 03, 2022	BUY	$28.79 - $35.41 $41,716 - $51,309	1,449 Added 2.93%	50,939 $1.72 Million
Q2 2022 Aug 12, 2022	SELL	$25.33 - $34.25 $444,693 - $601,293	-17,556 Reduced 26.19%	49,490 $1.43 Million
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $300,837 - $347,160	-10,552 Reduced 13.6%	67,046 $2.17 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $398,134 - $516,653	15,098 Added 24.16%	77,598 $2.26 Million
Q3 2021 Nov 09, 2021	BUY	$23.54 - $31.39 $662,227 - $883,063	28,132 Added 81.86%	62,500 $1.67 Million
Q2 2021 Aug 13, 2021	SELL	$26.72 - $33.19 $1.93 Million - $2.4 Million	-72,390 Reduced 67.81%	34,368 $1.06 Million
Q1 2021 May 13, 2021	SELL	$24.15 - $31.45 $336,385 - $438,067	-13,929 Reduced 11.54%	106,758 $2.8 Million
Q4 2020 Feb 11, 2021	SELL	$17.7 - $25.81 $618,455 - $901,827	-34,941 Reduced 22.45%	120,687 $3.04 Million
Q3 2020 Nov 12, 2020	BUY	$20.2 - $25.05 $313,807 - $389,151	15,535 Added 11.09%	155,628 $3.24 Million
Q2 2020 Aug 12, 2020	BUY	$17.09 - $24.89 $797,265 - $1.16 Million	46,651 Added 49.93%	140,093 $3.33 Million
Q1 2020 May 13, 2020	BUY	$14.45 - $24.69 $79,576 - $135,967	5,507 Added 6.26%	93,442 $1.68 Million
Q4 2019 Feb 10, 2020	BUY	$19.93 - $29.13 $528,284 - $772,148	26,507 Added 43.15%	87,935 $2.09 Million
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $43,324 - $56,762	-1,701 Reduced 2.69%	61,428 $1.69 Million
Q2 2019 Aug 14, 2019	SELL	$29.96 - $38.87 $551,054 - $714,935	-18,393 Reduced 22.56%	63,129 $2.09 Million
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $410,935 - $526,554	12,540 Added 18.18%	81,522 $2.86 Million
Q4 2018 Feb 14, 2019	SELL	$30.84 - $49.51 $368,877 - $592,189	-11,961 Reduced 14.78%	68,982 $2.29 Million
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $2.39 Million - $3.17 Million	56,081 Added 225.57%	80,943 $4.08 Million
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $23,946 - $32,498	543 Added 2.23%	24,862 $1.49 Million
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $484,696 - $611,904	13,047 Added 115.75%	24,319 $1.11 Million
Q4 2017 Feb 14, 2018	BUY	$36.4 - $42.6 $289,889 - $339,266	7,964 Added 240.75%	11,272 $450,000
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $121,569 - $164,242	3,308	3,308 $133,000

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account